Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Mar 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain substances in the blood, called sphingolipids, might affect the success of radiotherapy in treating liver cancer, specifically hepatocellular carcinoma. Researchers believe that by measuring the levels of these sphingolipids, they can learn more about how well the radiotherapy is working for patients. The study will collect blood samples from patients undergoing radiotherapy and analyze these samples to see if there's a connection between sphingolipid levels and treatment outcomes.

To participate in this trial, patients need to be between 18 and 80 years old, have a confirmed diagnosis of primary liver cancer, and be scheduled to receive radiotherapy. They should also expect to live for at least three more months. However, individuals with other cancers, certain severe health conditions, or those who cannot complete their treatment will not be eligible. Participants will contribute to important research that could help improve treatment for liver cancer patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients voluntarily signed the informed consent form.
• • Aged between 18 and 80 years.
• • Clinically diagnosed with primary liver cancer according to the latest treatment guidelines.
• • Determined by the treating physician to require radiotherapy.
• • Expected survival time of more than 3 months.
• Exclusion Criteria:
• • Patients who discontinued radiotherapy or did not complete the planned treatment.
• • Presence of malignancies from other origins.
• • Severe metabolic diseases such as uncontrolled diabetes, significant obesity, or fatty liver disease.
• • Uncontrolled comorbidities, such as severe cardiovascular or pulmonary diseases, that may affect treatment or study outcomes.